Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.

Basic Information

ID: ALA1138920

Journal: Bioorg Med Chem Lett

Title: Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.

Authors: Kim ND, Yoon J, Kim JH, Lee JT, Chon YS, Hwang MK, Ha I, Song WJ.

Abstract: Mental retardation is the most common and debilitating condition for individuals with Down syndrome (DS). The hyper-activation of DYRK1A by overexpression causes significant learning and memory deficits in DS-model mice. Thus far, no mechanism-based drug has been developed to address this. After a combination of in silico and in vitro screenings, two DYRK1A inhibitors were isolated that are active in a cell-based assay. Further optimization could lead to a novel drug discovery that could address DS learning and memory deficits.

CiteXplore: 16698266

DOI: 10.1016/j.bmcl.2006.04.042

Patent ID: ┄